Clinical Trials Logo

Ovarian Neoplasms clinical trials

View clinical trials related to Ovarian Neoplasms.

Filter by:

NCT ID: NCT03402841 Completed - Clinical trials for Non-Germline BRCA Mutated Ovarian Cancer

Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients

OPINION
Start date: January 30, 2018
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the efficacy and safety of single-agent olaparib as a maintenance treatment in patients with relapsed High Grade Serous Ovarian Cancer (including patients with primary peritoneal and/or fallopian tube cancer) or high grade endometrioid cancer who do not have known deleterious or suspected deleterious germline BRCA mutations (non-gBRCAm) and who had responded following platinum based chemotherapy

NCT ID: NCT03400306 Withdrawn - Cancer - Ovarian Clinical Trials

A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

Start date: November 15, 2021
Phase: Phase 1
Study type: Interventional

This study will evaluate the bioavailability between the veliparib tablet formulation to the capsule formulation; and will assess the effect of food on veliparib bioavailability in participants with ovarian cancer.

NCT ID: NCT03399344 Recruiting - Ovarian Cancer Clinical Trials

Clinical Impact of Dedicated MR Staging of Ovarian Cancer

MRStagingOC
Start date: April 13, 2018
Phase: N/A
Study type: Interventional

The only chance of cure for patients with advanced stage ovarian cancer is complete cytoreductive surgery (CRS). The only way to determine whether complete CRS can be achieved is by a laparoscopy. However, diffusion-weighted magnetic resonance imaging (DW-MRI) has a very high sensitivity to detect small volume malignant disease, making it a potentially suitable staging tool. Aim of this study is to determine the performance of DW-MRI for predicting whether complete CRS can be achieved.

NCT ID: NCT03398655 Completed - Clinical trials for Recurrent Platinum Resistant Ovarian Cancer

A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)

OVAL
Start date: December 19, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.

NCT ID: NCT03395080 Completed - Ovarian Cancer Clinical Trials

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma

P204
Start date: March 5, 2018
Phase: Phase 2
Study type: Interventional

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma

NCT ID: NCT03394885 Completed - Ovarian Cancer Clinical Trials

Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer

AdORN
Start date: June 19, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to validate a safe dose of atezolizumab with dose-dense paclitaxel and carboplatin when utilized with neoadjuvant chemotherapy and interval cytoreductive surgery followed by maintenance atezolizumab in women with advanced ovarian cancer.

NCT ID: NCT03393962 Suspended - Ovarian Cancer Clinical Trials

Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors

Start date: December 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-arm, open-label, phase I/II trial to evaluate the safety and efficacy of ovarian cancer-specific, engineered immune effectors (OC-EIEs) in women.

NCT ID: NCT03393884 Active, not recruiting - Clinical trials for Fallopian Tube Cancer

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

OVATION 2
Start date: September 5, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.

NCT ID: NCT03393507 Recruiting - Ovarian Cancer Clinical Trials

A Study of Apatinib Treatment in for Advanced Ovarian Cancer

Start date: August 1, 2017
Phase: Phase 2
Study type: Interventional

The study is evaluated the effacy and safety of apatinib combined with chemotherapy in the advanced ovarian cancer

NCT ID: NCT03388996 Recruiting - Ovarian Neoplasms Clinical Trials

Pelvic Microbiomes of Benign and Malignant Ovarian Diseases

MTBOD-1
Start date: January 1, 2018
Phase:
Study type: Observational

This case-control study aims to compare the pelvic microbiomes of benign ovarian diseases and ovarian malignancies by 16s RNA techniques and culture. Discharges/flushing fluid from vagina, faces and fimbria end of fallopian tube are collected from age and menopausal status matched patient before and during procedures of laparoscopies. The discharges/flushing fluid would be sent for 16s RNA analysis and microculture respectively, and the results would get self-contrasted comparison and case-control comparison.